Quero Francisco B, Troncoso-Bravo Tays, Farías Mónica A, Kalergis Alexis M
Millennium Institute on Immunology and Immunotherapy, Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, Santiago, Chile.
Departamento de Endocrinología, Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.
Immunotargets Ther. 2025 Apr 28;14:501-514. doi: 10.2147/ITT.S513629. eCollection 2025.
Currently, the management of autoimmune disorders still being a challenge in terms of safety, efficiency, and specificity. Cell-based therapeutic strategies have emerged as a novel approach for autoimmune disease treatment, employing different cell therapy platforms, including tolerogenic dendritic cells, regulatory T cells, conventional and regulatory chimeric antigen receptor-T cells, mesenchymal and hematopoietic stem cells, each with their biological features. Here, we discuss the different cell therapy platforms, their immunological mechanisms of action, their therapeutic potential and benefits in autoimmune diseases, and challenges related to their production, scaling up, risks, and patient safety.
Immunotargets Ther. 2025-4-28
Semin Immunopathol. 2025-1-16
J Allergy Clin Immunol. 2025-3
Int J Mol Sci. 2020-9-23
Best Pract Res Clin Haematol. 2024-9
Bone Marrow Transplant. 2025-1
NEJM Evid. 2024-7
Chin Med J (Engl). 2024-5-20
N Engl J Med. 2024-2-22
Nat Commun. 2024-2-6